Mass Spectrometry Analysis of the Exhaled Breath Condensate and Proposal of Dermcidin and S100A9 as Possible Markers for Lung Cancer Prognosis
ConclusionExhaled breath condensate analysis combined with MS technique may become a valuable method for lung cancer screening and Dermcidin and S100A9 may serve as biomarkers for lung cancer diagnosis or prognosis.
CONCLUSIONUsing 3D-MDCT, we could accurately divide A4 + 5 and safely perform the surgery.
We describe our evaluation, validation, and implementation of this system for routine testing of BRAF, EGFR, KRAS, and NRAS using formalin-fixed, paraffin-embedded cancer samples. All four Idylla test systems showed excellent concordance with reference methods. The analytical sensitivity ranged from 94.66% to 100%, depending on the cartridge, and specificity was 100%. A few discordant results were noted and further investigated: KRAS Q61L was misclassified as Q61H; KRAS Q61R was not identified; there was a false-negative EGFR double mutation (L861Q and G719A); and there was a false-negative EGFR double mutation (T790M and ...
LUNG cancer symptoms tend to develop as the condition progresses, but because there ’s no cure, it’s extremely important to recognise any signs as early on as possible. A person’s cough could signal the potentially life-threatening condition.
Publication date: Available online 20 August 2019Source: Pharmacological ResearchAuthor(s): Hong-Yuan Lu, Yu-Xin Zu, Xiao-Wen Jiang, Xiao-Tong Sun, Tian-Yi Liu, Ruo-Lan Li, Qiong Wu, Ying-Shi Zhang, Qing-Chun ZhaoAbstractAcquired drug-resistant non-small cell lung cancer (NSCLC) has strong proliferation ability and is prone to epithelial-mesenchymal transition (EMT) and subsequent metastasis. Notch pathway mediates cell survival and EMT and is involved in the induction of multidrug resistance (MDR). ZLDI-8 is an inhibitor of Notch activating/cleaving enzyme ADAM-17 we found before. However, the effects of ZLDI-8 on resista...
Nivolumab, a checkpoint inhibitor of programmed cell death receptor-1 (PD-1), is used in the treatment of metastatic melanoma and nonsmall cell lung cancer. Blockade of PD-1 receptor releases inhibition of T-cell activation and allows for an antitumor immune response. As with many immune-mediated therapeutics, the most common cutaneous immune-related adverse events reported in association with nivolumab are vitiligo, rash and pruritis. Other autoimmune and inflammatory skin conditions such as psoriasiform or lichenoid eruptions, autoimmune blistering disorders, and sarcoidosis have also been reported.
We present the case of a patient with paraneoplastic acral vascular syndrome as an initial manifestation of lung cancer.
Background: Poziotinib is a potent, orally available, EGFR and HER2 exon 20-selective tyrosine kinase inhibitor used to treat nonsmall cell lung cancer (NSCLC). During a Phase 2 clinical trial of poziotinib, a high incidence of cutaneous reactions were reported in treated patients. Up to 55% of patients received a dose reduction in response to adverse events, most commonly from skin reaction and diarrhea.
Immune checkpoint inhibition is an increasingly common therapy for various cancers including melanoma and nonsmall cell lung cancer. Inhibition of the cytotoxic T lymphocyte antigen-4 (CTLA-4) or the programmed death receptor-1 (PD-1)/ PD ligand-1 (PD-L1) signaling pathways enhance T cell activation and promotes cytotoxic activity against cancer cells. However, the nonspecific response promoted by these inhibitors have led to a variety of adverse dermatologic effects. We review the case of a progressive lichenoid eruption in a patient on nivolumab and review cutaneous toxicities from this class of medications.
Condition: Lung Cancer Interventions: Other: Bronchoscopy; Other: Research Procedures Sponsors: NYU Langone Health; National Cancer Institute (NCI) Not yet recruiting
Condition: Extensive Stage Small Cell Lung Cancer Interventions: Drug: HLX10; Drug: carboplatin and etoposide; Drug: placebo Sponsor: Shanghai Henlius Biotech Recruiting